Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer
Open Access
- 1 June 2015
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 10 (6), 883-889
- https://doi.org/10.1097/jto.0000000000000517
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsJournal of Clinical Oncology, 2013
- Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012Journal of Thoracic Oncology, 2013
- Health-related quality of life questionnaires in lung cancer trials: a systematic literature reviewHealth Economics Review, 2012
- Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family BlockerJournal of Pharmacology and Experimental Therapeutics, 2012
- The value of progression-free survival to patients with advanced-stage cancerNature Reviews Clinical Oncology, 2011
- Health-Related Quality of Life in Non–Small-Cell Lung Cancer: An Update of a Systematic Review on Methodologic Issues in Randomized Controlled TrialsJournal of Clinical Oncology, 2011
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- Analysis of Longitudinal DataTechnometrics, 1995
- The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trialsEuropean Journal Of Cancer, 1994
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993